netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Ipilimumab found 17 matches

Formulary items 3 matches
Sub Section Title / notes 1 match
   
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Ipilimumab  (Yervoy®) Malignant disease and immunosuppression - Ipilimumab - 08.01.05
  Cytotoxic Drug Nivolumab  (Opdivo®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Pembrolizumab  (Keytruda®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (Jan 2019): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (08.01.05)
link in drug section NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (08.01.05)
link in drug section NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (08.01.05)
link in drug section NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (08.01.05)
link in drug section NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (08.01.05)
link in drug section NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab (08.01.05)
link in drug section NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma (08.01.05)
link in drug section NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma (08.01.05)
link in drug section NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (08.01.05)
link in drug section NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small- cell lung cancer (08.01.05)
link in drug section NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (08.01.05)
link in drug section NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (08.01.05)
link in drug section NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (08.01.05)

SubSection Titles / notes  
Ipilimumab - (08.01.05)

 
netFormulary